Comparison Overview

Mahakam Beta Farma

VS

Merck KGaA, Darmstadt, Germany

Mahakam Beta Farma

Jalan Pulo Kambing Raya No 9 Rawa Terate, Jakarta 13920, ID
Last Update: 2025-03-15 (UTC)
Between 750 and 799

We are an innovative, competitive and leading pharmaceutical and healthcare company with strong brands and sustainable double digits growth. We are proud to deliver high quality products and excellent services to our customers so they can have better lives.

NAICS: 325
NAICS Definition:
Employees: 1,001-5,000
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Merck KGaA, Darmstadt, Germany

Frankfurter Str. 250, Darmstadt, undefined, 64293, DE
Last Update: 2025-03-05 (UTC)
Between 800 and 849

We are Merck KGaA, Darmstadt, Germany and its global affiliates. We are a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Privacy Statement: https://www.emdgroup.com/en/privacy-statement.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,394
Subsidiaries: 3
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/mahakam-beta-farma.jpeg
Mahakam Beta Farma
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/emd-affiliates-of-merck-kgaa-darmstadt-germany.jpeg
Merck KGaA, Darmstadt, Germany
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Mahakam Beta Farma
100%
Compliance Rate
0/4 Standards Verified
Merck KGaA, Darmstadt, Germany
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Mahakam Beta Farma in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Merck KGaA, Darmstadt, Germany in 2025.

Incident History — Mahakam Beta Farma (X = Date, Y = Severity)

Mahakam Beta Farma cyber incidents detection timeline including parent company and subsidiaries

Incident History — Merck KGaA, Darmstadt, Germany (X = Date, Y = Severity)

Merck KGaA, Darmstadt, Germany cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/mahakam-beta-farma.jpeg
Mahakam Beta Farma
Incidents

No Incident

https://images.rankiteo.com/companyimages/emd-affiliates-of-merck-kgaa-darmstadt-germany.jpeg
Merck KGaA, Darmstadt, Germany
Incidents

No Incident

FAQ

Merck KGaA, Darmstadt, Germany company demonstrates a stronger AI Cybersecurity Score compared to Mahakam Beta Farma company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Merck KGaA, Darmstadt, Germany company has disclosed a higher number of cyber incidents compared to Mahakam Beta Farma company.

In the current year, Merck KGaA, Darmstadt, Germany company and Mahakam Beta Farma company have not reported any cyber incidents.

Neither Merck KGaA, Darmstadt, Germany company nor Mahakam Beta Farma company has reported experiencing a ransomware attack publicly.

Neither Merck KGaA, Darmstadt, Germany company nor Mahakam Beta Farma company has reported experiencing a data breach publicly.

Neither Merck KGaA, Darmstadt, Germany company nor Mahakam Beta Farma company has reported experiencing targeted cyberattacks publicly.

Neither Mahakam Beta Farma company nor Merck KGaA, Darmstadt, Germany company has reported experiencing or disclosing vulnerabilities publicly.

Neither Mahakam Beta Farma nor Merck KGaA, Darmstadt, Germany holds any compliance certifications.

Neither company holds any compliance certifications.

Merck KGaA, Darmstadt, Germany company has more subsidiaries worldwide compared to Mahakam Beta Farma company.

Merck KGaA, Darmstadt, Germany company employs more people globally than Mahakam Beta Farma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Mahakam Beta Farma nor Merck KGaA, Darmstadt, Germany holds SOC 2 Type 1 certification.

Neither Mahakam Beta Farma nor Merck KGaA, Darmstadt, Germany holds SOC 2 Type 2 certification.

Neither Mahakam Beta Farma nor Merck KGaA, Darmstadt, Germany holds ISO 27001 certification.

Neither Mahakam Beta Farma nor Merck KGaA, Darmstadt, Germany holds PCI DSS certification.

Neither Mahakam Beta Farma nor Merck KGaA, Darmstadt, Germany holds HIPAA certification.

Neither Mahakam Beta Farma nor Merck KGaA, Darmstadt, Germany holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X